miRNAs orchestration of testicular germ cell tumors – Particular emphasis on diagnosis, progression and drug resistance

• Published in: Pathology, research and practice research and practice, 2023-08, Vol.248, p.154612-154612, Article 154612
• Main Authors: Elesawy, Ahmed E., Abulsoud, Ahmed I., Moustafa, Hebatallah Ahmed Mohamed, Elballal, Mohammed S., Sallam, Al-Aliaa M., Elazazy, Ola, El-Dakroury, Walaa A., Abdel Mageed, Sherif S., Abdelmaksoud, Nourhan M., Midan, Heba M., Shahin, Reem K., Elrebehy, Mahmoud A., Nassar, Yara A., Elazab, Ibrahim M., Elballal, Ahmed S., Elballal, Mai S., Doghish, Ahmed S.
• Format: Article
• Language: English
• Subjects: Diagnosis; MiRNA; Prognosis; Testicular cancer, Drug resistance; Testicular germ cell tumors (TGCTs)
• ISSN: 0344-0338; 1618-0631
• DOI: 10.1016/j.prp.2023.154612

Testicular cancer (TC) is one of the most frequently incident solid tumors in males. A growing prevalence has been documented in developed countries. Although recent advances have made TC an exceedingly treatable cancer, numerous zones in TC care still have divisive treatment decisions. In addition to physical examination and imaging techniques, conventional serum tumor markers have been traditionally used for the diagnosis of testicular germ cell tumors (TGCT). Unlike other genital and urinary tract tumors, recent research methods have not been broadly used in TGCTs. Even though several challenges in TC care must be addressed, a dedicated group of biomarkers could be particularly beneficial to help classify patient risk, detect relapse early, guide surgery decisions, and tailor follow-up. Existing tumor markers (Alpha-fetoprotein, human chorionic gonadotrophin, and lactate dehydrogenase) have limited accuracy and sensitivity when used as diagnostic, prognostic, or predictive markers. At present, microRNAs (miRNA or miR) play a crucial role in the process of several malignancies. The miRNAs exhibit pronounced potential as novel biomarkers since they reveal high stability in body fluids, are easily detected, and are relatively inexpensive in quantitative assays. In this review, we aimed to shed light on the recent novelties in developing microRNAs as diagnostic and prognostic markers in TC and discuss their clinical applications in TC management.